Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy.

Klippenstein P, Schlomm T, von Amsberg G, Beyer B, Pompe RS, Michl U, Salomon G, Thederan I, Budäus L, Heinzer H, Tilki D, Haese A, Huland H, Graefen M, Steuber T, Tennstedt P.

Urol Oncol. 2019 Sep;37(9):575.e1-575.e7. doi: 10.1016/j.urolonc.2019.04.007. Epub 2019 Apr 30.

PMID:
31047783
2.

Oncological outcome after radical prostatectomy: Marital status does not make a difference.

Schiffmann J, Beyer B, Tennstedt P, Boehm K, Mehring G, Schlomm T, Salomon G, Karakiewicz P, Graefen M.

Int J Urol. 2015 May;22(5):484-9. doi: 10.1111/iju.12717. Epub 2015 Mar 17.

3.

Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: Analysis of 359 cases with a median follow-up period of 26 months.

Abdel Raheem A, Chang KD, Alenzi MJ, Ham WS, Han WK, Choi YD, Rha KH.

Int J Urol. 2018 Dec;25(12):1006-1014. doi: 10.1111/iju.13808. Epub 2018 Oct 1.

PMID:
30276864
4.

Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.

Loeb S, Zhu X, Schroder FH, Roobol MJ.

BJU Int. 2012 Dec;110(11):1678-83. doi: 10.1111/j.1464-410X.2012.11367.x. Epub 2012 Sep 21.

5.

Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database.

Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Boffetta P, Freedland SJ.

Cancer. 2014 Jan 15;120(2):197-204. doi: 10.1002/cncr.28423. Epub 2013 Oct 11. Erratum in: Cancer. 2015 Dec 1;121(23):4272.

6.

The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.

Ham WS, Chalfin HJ, Feng Z, Trock BJ, Epstein JI, Cheung C, Humphreys E, Partin AW, Han M.

J Urol. 2017 Apr;197(4):1060-1067. doi: 10.1016/j.juro.2016.11.079. Epub 2016 Nov 12.

PMID:
27847296
7.

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW.

JAMA. 2005 Jul 27;294(4):433-9.

PMID:
16046649
8.

Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multi-institutional database.

Schiavina R, Bianchi L, Borghesi M, Briganti A, Brunocilla E, Carini M, Terrone C, Mottrie A, Dente D, Gacci M, Gontero P, Gurioli A, Imbimbo C, La Manna G, Marchioro G, Milanese G, Mirone V, Montorsi F, Morgia G, Munegato S, Novara G, Panarello D, Porreca A, Russo GI, Serni S, Simonato A, Urzì D, Verze P, Volpe A, Martorana G.

Int J Urol. 2016 Dec;23(12):1000-1008. doi: 10.1111/iju.13203. Epub 2016 Sep 12.

9.

Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.

Lee BH, Kibel AS, Ciezki JP, Klein EA, Reddy CA, Yu C, Kattan MW, Stephenson AJ.

Eur Urol. 2015 Feb;67(2):204-9. doi: 10.1016/j.eururo.2014.09.017. Epub 2014 Oct 5.

PMID:
25294696
10.

The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.

Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, Suardi N, Moschini M, Dell'Oglio P, Schiavina R, Montorsi F, Briganti A.

Eur Urol. 2016 Jun;69(6):1142-8. doi: 10.1016/j.eururo.2015.12.010. Epub 2015 Dec 31.

PMID:
26749093
11.

Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.

Brockman JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, Lin DW, Bianco FJ Jr, Rabah DM, Klein EA, Ciezki JP, Gao T, Kattan MW, Stephenson AJ.

Eur Urol. 2015 Jun;67(6):1160-1167. doi: 10.1016/j.eururo.2014.09.019. Epub 2014 Oct 6.

12.

NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.

Moul JW, Sarno MJ, McDermed JE, Triebell MT, Reynolds MA.

Urology. 2014 Dec;84(6):1427-32. doi: 10.1016/j.urology.2014.07.059.

PMID:
25432832
13.

New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.

Ham WS, Chalfin HJ, Feng Z, Trock BJ, Epstein JI, Cheung C, Humphreys E, Partin AW, Han M.

Eur Urol. 2017 Jun;71(6):907-912. doi: 10.1016/j.eururo.2016.11.006. Epub 2016 Nov 19.

PMID:
27876305
14.

Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis.

Shao YH, Kim S, Moore DF, Shih W, Lin Y, Stein M, Kim IY, Lu-Yao GL.

Eur Urol. 2014 Apr;65(4):693-700. doi: 10.1016/j.eururo.2013.05.023. Epub 2013 May 21.

15.

[Clinical study of radical prostatectomy for prostate cancer from a single institution].

Ishida R, Kobayashi H, Yoshida S, Ogawa M, Shiota T, Nishikimi T, Yamada H, Yokoi K.

Nihon Hinyokika Gakkai Zasshi. 2009 Sep;100(6):615-24. Japanese.

PMID:
19827538
16.

Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.

Boehm K, Schiffmann J, Tian Z, Lesmana H, Larcher A, Mandel P, Karakiewicz PI, Graefen M, Schwarz R, Krüll A, Tilki D.

Urol Oncol. 2016 Mar;34(3):119.e11-8. doi: 10.1016/j.urolonc.2015.09.012. Epub 2015 Oct 23.

PMID:
26602027
17.

Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.

Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED.

JAMA. 2006 Nov 15;296(19):2329-35.

PMID:
17105795
18.

Do Second Primary Cancers Affect the Risk of Biochemical Recurrence in Prostate Cancer Patients Undergoing Radical Prostatectomy? A Propensity Score-Matched Analysis.

Kang M, Jung JW, Oh JJ, Lee S, Hong SK, Lee SE, Byun SS.

Clin Genitourin Cancer. 2016 Aug;14(4):e363-9. doi: 10.1016/j.clgc.2016.03.003. Epub 2016 Mar 10.

PMID:
27105723
19.

Impact of Radical Prostatectomy on Long-Term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration.

Bhindi B, Rangel LJ, Mason RJ, Gettman MT, Frank I, Kwon ED, Tollefson MK, Thompson RH, Boorjian SA, Karnes RJ.

J Urol. 2017 Jul;198(1):86-91. doi: 10.1016/j.juro.2017.01.063. Epub 2017 Jan 24.

PMID:
28130104
20.

Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.

Patel DN, Jha S, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Chapin BF, Freedland SJ.

Int J Urol. 2018 Dec;25(12):998-1004. doi: 10.1111/iju.13806. Epub 2018 Sep 25.

PMID:
30253446

Supplemental Content

Support Center